公开(公告)号：US20240299413A1

公开(公告)日：2024-09-12

申请号：US18260778

申请日：2021-08-06

申请人： EICOS SCIENCES, INC.

发明人： Wade W. BENTON ,  Kevin A. CHRISTAL

IPC分类号： A61K31/5578 ,  A61P19/04

CPC分类号： A61K31/5578 ,  A61P19/04

摘要： The present disclosure generally relates to treatment of systemic sclerosis with symptomatic Raynaud's Phenomenon by intravenous or subcutaneous administration of iloprost or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20210128680A1

公开(公告)日：2021-05-06

申请号：US16669495

申请日：2019-10-30

申请人： Chang Gung University ,  Chang Gung Memorial Hospital, Linkou

发明人： Ying-Ju LAI ,  Pao-Hsien CHU ,  Whei-Yang Winston KAO

IPC分类号： A61K38/16 ,  A61P9/12 ,  A61K31/5585 ,  A61K31/5578 ,  A61K31/505 ,  A61K31/519 ,  A61K31/4985 ,  A61K31/4422 ,  A61K31/554 ,  A61K31/506 ,  A61K31/366

摘要： Provided herein are synthetic peptides and methods for treating cardiorespiratory diseases, particularly cardiopulmonary disorder (CPD) by use of the synthetic peptides. The present synthetic peptide has the amino acid sequence of X1EX2LRVANEVTLN (SEQ ID NO: 1), in which X1 is tyrosine (Y) or phenylalanine (F), and X2 is alanine (A) or cysteine (C). In preferred embodiments, an effective amount of the present synthetic peptide is administered to a subject suffering from CPD to ameliorate or alleviate symptoms associated therewith.

公开(公告)号：US10709715B2

公开(公告)日：2020-07-14

申请号：US16207597

申请日：2018-12-03

申请人： Cipla Limited

发明人： Geena Malhotra ,  Kalpana Joshi ,  Jeevan Ghosalkar

IPC分类号： A61K31/522 ,  A61K31/5575 ,  A61K31/5578 ,  A61P9/12 ,  C07D487/04 ,  A61K31/5585 ,  A61K31/513 ,  A61K9/00

摘要： Disclosed herein are methods of treating pulmonary hypertension, including pulmonary arterial hypertension, by administering to a patient in need thereof an effective amount of temozolomide, optionally in conjunction with one or more additional therapeutic agents. Compositions and kits including temozolomide for use in treating pulmonary hypertension, including pulmonary arterial hypertension, are also disclosed.

公开(公告)号：US20180221385A1

公开(公告)日：2018-08-09

申请号：US15747532

申请日：2016-07-28

申请人： SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SCIENCES SANTE ET

发明人： Jean-luc ARDILOUZE ,  aude GAGNON-AUGER ,  Fernand GOBEIL ,  Julie MENARD ,  Jean-Patrice BAILLARGEON ,  Pascal BRASSARD

IPC分类号： A61K31/5578 ,  A61P3/10 ,  A61K9/00 ,  A61K38/28 ,  A61K45/06

CPC分类号： A61K31/5578 ,  A61K9/0019 ,  A61K31/137 ,  A61K31/472 ,  A61K31/519 ,  A61K31/557 ,  A61K31/5585 ,  A61K38/28 ,  A61K45/06 ,  A61P3/10 ,  C07D215/20 ,  C07D217/20 ,  C07D487/04 ,  C07K14/62 ,  A61K2300/00

摘要： The present disclosure relates to compositions and combinations comprising one or more insulin(s) and one or more vasoactive agent(s), and use thereof for increasing subcutaneous insulin absorption and/or treating diabetes and/or treating or preventing hyperglycemia or complications in a patient in need thereof.

公开(公告)号：US20160303040A1

公开(公告)日：2016-10-20

申请号：US15037494

申请日：2014-11-18

申请人： RIGSHOSPITALET

发明人： Pär Johansson ,  Philip Hansen ,  Jens Kindtler

IPC分类号： A61K9/00 ,  A61K47/18 ,  A61K31/5578

CPC分类号： A61K9/0019 ,  A61K31/5578 ,  A61K47/183

摘要： The present invention relates to injectable pharmaceutical compositions showing improved storage stability said compositions comprising iloprost.

摘要翻译： 本发明涉及显示改善的储存稳定性的可注射药物组合物，所述组合物包含伊洛前列素。

公开(公告)号：US20100184862A1

公开(公告)日：2010-07-22

申请号：US12520493

申请日：2007-12-21

申请人： Roger Tung

发明人： Roger Tung

IPC分类号： A61K31/5578 ,  C07C59/46 ,  A61P9/12 ,  A61P13/12 ,  A61P35/00 ,  C12N5/00

CPC分类号： C07C405/0083 ,  C07B2200/05 ,  C07C2602/22

摘要： This invention relates to novel prostacyclin derivatives, their acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by prostacyclin, and in particular those diseases and conditions beneficially treated by dilators of systemic and pulmonary arterial vascular beds or by platelet aggregation inhibitors.

摘要翻译： 本发明涉及新型前列环素衍生物，其可接受的酸加成盐，溶剂合物，水合物及其多晶型物。 本发明还提供了包含本发明化合物和这些组合物在治疗由前列环素有益治疗的疾病和病症的方法中的用途，特别是那些通过全身和肺动脉血管床的扩张器或血小板有利地治疗的疾病和病症 聚集抑制剂。

公开(公告)号：US06992093B2

公开(公告)日：2006-01-31

申请号：US10352768

申请日：2003-01-27

申请人： John S. Torday ,  Virender K. Rehan

发明人： John S. Torday ,  Virender K. Rehan

IPC分类号： A61K31/4402 ,  A61K31/427 ,  A61K31/5578

CPC分类号： A61K31/4439 ,  A61K31/00 ,  A61K49/0004

摘要： Methods of inhibiting lipofibroblast to myofibroblast transdifferentiation in a mammal are disclosed comprising administering a PPAR gamma ligand when said mammal is exposed to a hyperoxic condition.

摘要翻译： 公开了抑制脂肪成纤维细胞对哺乳动物肌成纤维细胞转分化的方法，其包括当所述哺乳动物暴露于高氧条件时施用PPARγ配体。

公开(公告)号：US5849791A

公开(公告)日：1998-12-15

申请号：US461334

申请日：1995-06-05

申请人： Johan Wilhelm Stjernschantz ,  Bahram Resul

发明人： Johan Wilhelm Stjernschantz ,  Bahram Resul

IPC分类号： A61K31/00 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5578 ,  A61P9/02 ,  A61P27/00 ,  A61P27/02 ,  A61P27/06 ,  C07C405/00

CPC分类号： C07C405/00 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5578 ,  Y10S514/913

摘要： The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.

公开(公告)号：US5422368A

公开(公告)日：1995-06-06

申请号：US986943

申请日：1992-12-08

申请人： Johan W. Stjernschantz ,  Bahram Resul

发明人： Johan W. Stjernschantz ,  Bahram Resul

IPC分类号： A61K31/00 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5578 ,  A61P9/02 ,  A61P27/00 ,  A61P27/02 ,  A61P27/06 ,  C07C405/00

CPC分类号： C07C405/00 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5578 ,  Y10S514/913

摘要： The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.

公开(公告)号：US11097034B2

公开(公告)日：2021-08-24

申请号：US16468547

申请日：2017-12-11

申请人： CASE WESTERN RESERVE UNIVERISTY ,  UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

发明人： Eben Alsberg ,  Oju Jeon ,  Ralph Marcucio ,  Chelsea Bahney ,  Diane Hu ,  Sarah Knox

IPC分类号： A61K31/221 ,  A61K31/5578 ,  A61L27/38 ,  A61K35/28 ,  A61K38/20 ,  A61K35/32 ,  A61K45/06

摘要： A method of modulating transdifferentiation of chondrocytes to osteoblast includes administering to the chondrocytes an agent that modulates GP130 receptor signaling and expression of at least one of Sox2, Oct4, or Nanog of the chondrocytes.